undamentalytics Newsletter
Sign in

Pulmatrix, Inc. (PULM) stock

Add to watchlist

Add holding +

NASDAQ: PULM Nasdaq Biotechnology Next results ~November 13, 2026

Pulmatrix, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

The Fundamentalytics view

Next results ~November 13, 2026 (estimated)

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Pulmatrix, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Results due soon. Results are expected around 13 November; the share price can move sharply on the day.
  • Volatile shares. Over the past year the shares showed annualised volatility of 87% and a beta of 0.0 against the S&P 500.

Latest results

Earnings per share
-$1.03 against an average estimate of -$1.05: beat by 1.9%
Share reaction
-3.7% in the first session after the results on August 13, 2026, against +0.5% for the S&P 500

Pulmatrix's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day0.0%
  • 1 week-2.8%
  • 1 month-10.8%
  • This year-37.2%
  • 1 year-71.6%
  • 5 years-91.7%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 13, 2026
Next results (est.)
November 13, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Shareholder vote
  2. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Pulmatrix, Inc. valuation models and calculator

No model value for Pulmatrix, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Pulmatrix, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.2%: the 10-year Treasury yield (4.9%) plus a beta of 0.72 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no twelve-month earnings or share count in the filings yet
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: no twelve-month earnings or share count in the filings yet
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: no twelve-month earnings or share count in the filings yet
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no twelve-month earnings or share count in the filings yet
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Pulmatrix, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Pulmatrix, Inc.: too few analysts cover it.

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2023 −$1.05 −$1.03 +1.9%
Jun 2023 −$1.23 −$1.04 +15.4%
Dec 2022 −$1.44 −$1.14 +20.8%

Adjusted EPS as companies report it, against the average analyst estimate.

Positioning

Short interest
1.2%
of tradable shares
Days to cover
1.39
at average volume
Short interest, 1 month
−22%
to October 15, 2026
Held by institutions
9%
of shares
Held by insiders
0.8%
of shares
Employees
2
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
PULM−63%−56%−52%+275%−68%−37%
Industry peers (median)−35%−57%−17%−29%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
PULM33%42%25%67%33%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
PULM−85%−65%−60%−29%−78%−64%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 3, 2015: 100% from November 25, 2015 to April 8, 2026. Getting back needed a 90656% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.19 – $4.89
From 52-week high
−71.4%
vs 50-day average
−5.7%
vs 200-day average
−17.8%
Volatility (1 year)
87%
Beta vs S&P 500
0.03

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
2 up, 10 down
typical move ±3.9%
After a week
5 up, 7 down
typical move ±28.0%
After a month
4 up, 8 down
typical move ±30.3%
Results releasedNext dayS&P 500 next day5 days21 days
August 13, 2026 −3.7% +0.5% −6.2% −9.4%
May 15, 2026 −0.8% −1.3% +5.5% +17.3%
February 26, 2026 −6.9% −1.0% −33.3% −57.6%
October 16, 2025 +1.2% −0.1% +1.9% −1.0%
August 6, 2025 −6.0% +0.7% −15.1% −11.1%
March 21, 2025 −5.8% +1.8% −5.4% −17.0%
November 8, 2024 −0.5% +0.5% +215.4% +186.5%
August 13, 2024 −0.9% +2.0% −11.8% −21.8%
May 10, 2024 −3.3% +0.1% +3.7% +4.1%
March 28, 2024 +7.4% −0.2% +24.0% +17.3%
January 8, 2024 −0.5% +1.3% −5.9% −15.4%
November 9, 2023 −9.4% +0.8% −7.8% −4.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 13, 2026 estimated from the company's past filing pattern, not announced

  • August 13, 2026
  • May 15, 2026
  • February 26, 2026
  • October 16, 2025
  • August 6, 2025
  • March 21, 2025

Recent SEC filings

Data status

When each part of this page on Pulmatrix, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Pulmatrix, Inc. in brief

What does Pulmatrix, Inc. do?
Pulmatrix, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Pulmatrix, Inc.'s stock ticker?
Pulmatrix, Inc. trades under the ticker PULM on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
When is Pulmatrix, Inc.'s next earnings date?
Around November 13, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Pulmatrix, Inc. announces its own schedule.